Dyadic Intl Inc Del Stock Price, News & Analysis

Dyadic International (Nasdaq: DYAI), a global biotechnology company specializing in precision engineered functional input proteins, has scheduled its second quarter 2025 financial results announcement and corporate update conference call for Wednesday, August 13, 2025, at 5:00 p.m. Eastern Time.

The company will host a conference call accessible via toll-free and international dial-in numbers, with a webcast available through their investor relations website. Participants can submit questions for the Q&A session by emailing them in advance.

Dyadic International (NASDAQ:DYAI), a global biotechnology company, has announced the pricing of its underwritten public offering of 6,052,000 shares of common stock. The offering is expected to close on August 1, 2025, with Craig-Hallum Capital Group LLC serving as the sole managing underwriter.

The company plans to use the net proceeds for working capital and general corporate purposes, including product development, sales, and marketing. The offering is being made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC.

Dyadic International (NASDAQ:DYAI), a global biotechnology company specializing in precision engineered functional input proteins, has announced a proposed underwritten public offering of common stock. The offering will be managed by Craig-Hallum Capital Group LLC as the sole underwriter.

The company plans to use the proceeds for working capital and general corporate purposes, including product development, sales, and marketing. The offering is being made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC. The final terms of the offering will be disclosed in a final prospectus supplement.

Dyadic International (NASDAQ:DYAI) announced its strategic rebranding to Dyadic Applied BioSolutions, effective in 30 days, marking its transition from research to commercial focus. The company, leveraging its proprietary C1 and Dapibus™ gene expression platforms, aims to commercialize non-therapeutic proteins for life sciences, food, nutrition, and industrial biotechnology applications.

Recent achievements include a $250,000 milestone payment from a non-animal dairy enzyme program and securing a $1.5 million second installment from a $3.0 million Gates Foundation grant for developing low-cost monoclonal antibodies. The company is on track to commercialize its input proteins in 2025.

Dyadic International (NASDAQ: DYAI) has announced a strategic leadership change, appointing Joe Hazelton as President while maintaining his COO role, to focus on commercializing ancillary recombinant protein products. The company has successfully pivoted over the past 18 months towards high-growth markets including cell culture media, DNA/RNA technologies, and non-animal food ingredients. Notable achievements include partnerships with Proliant Health for recombinant human albumin, a non-animal dairy enzyme collaboration, and a joint venture with Fermbox Bio leading to EN3ZYME's launch. The company's C1 and Dapibus platforms will continue supporting large-scale protein production. Mark Emalfarb remains CEO, focusing on biopharmaceutical programs, funding opportunities, and IP strategy. Hazelton, who joined Dyadic in 2021, brings over 20 years of biotech commercialization experience from roles at Dyadic and Novartis.

Dyadic International (NASDAQ: DYAI) reported Q1 2025 financial results and company progress. The biotechnology company is focusing on commercializing its proprietary Dapibus™ and C1 microbial protein production platforms for life science and industrial applications. Key developments include: a $4.5M research grant from CEPI and a $3.0M Gates Foundation grant for malaria and RSV antibody programs. The company is expanding its portfolio with six additional life science products and advancing toward commercialization in cell culture media, nucleic and industrial enzyme markets. Financial highlights show revenue increased to $394,000 (vs $335,000 in Q1 2024), while maintaining a cash position of $7.3M. Net loss slightly increased to $2.028M compared to $2.010M in the same period last year. The company is strategically pivoting toward developing scalable products with recurring revenue potential.

Dyadic International (NASDAQ: DYAI), a biotechnology company specializing in large-scale protein manufacturing for vaccines, therapeutics, and industrial applications, has scheduled its Q1 2025 financial results announcement and corporate update conference call for Wednesday, May 14, 2025, at 5:00 PM ET.

Shareholders and interested parties can access the call through toll-free (+1-877-407-0784) or international (+1-201-689-8560) numbers using Conference ID 13751387. A webcast will be available, with an archive accessible within 24 hours on Dyadic's Investor Relations website.

Dyadic International (Nasdaq: DYAI) has announced its participation in the 2025 World Vaccine Congress in Washington, D.C. CEO Mark Emalfarb will present on April 23, 2025, focusing on the company's C1 Platform and its application in addressing avian influenza (H5N1) and future pandemics.

The presentation, scheduled for 12:40 PM-1:10 PM in Room 202A, will showcase recent preclinical research utilizing Dyadic's proprietary C1 expression platform. The company will highlight data related to the production of non-mRNA antigens and reagents for vaccine production, demonstrating the platform's ability to elicit high neutralizing antibodies.

The C1 platform aims to enable rapid, cost-effective production of antigens, reagents, and cell culture media products to address global health challenges through scalable biomanufacturing. Interested parties can meet the management team at booth #654 or schedule meetings via assistant@dyadic.com.

Dyadic International (NASDAQ: DYAI) reported its 2024 financial results, highlighting significant progress in commercializing its Dapibus™ and C1 microbial protein production platforms. The company achieved $1.9 million in milestone and license revenue and secured up to $7.5 million in grants from CEPI and Gates Foundation.

Key financial metrics include:

• Total revenue increased to $3.5 million (vs $2.9 million in 2023)
• Net loss decreased to $5.8 million or $(0.20) per share (vs $6.8 million in 2023)
• Cash position of $9.3 million as of December 31, 2024

Notable developments include advancing Human Serum Albumin toward commercial launch in Q2 2025, expanding alternative protein portfolio with six life science products, and progressing in animal and human health applications. The company is developing multiple products nearing market launch, including DNASe1 and various enzymes for non-animal dairy applications.